Abstract
BACKGROUND: Breast cancer is one of the most common causes of cancer death in women both globally and in Iran. Although medical breakthroughs have improved its prognosis, different characteristics can vary locally, especially in understudied regions. Therefore, the present study was designed and carried out in 2022 to compare the rate of breast cancer recurrence in Luminal A and triple-negative patients referred to the Shahid Rahimi Hospital in Khorramabad from March 2019 to March 2020. MATERIALS AND METHODS: This study was a descriptive-analytical cross-sectional study designed and conducted on 59 patients diagnosed with Luminal A and triple-negative breast cancer treated at the Shahid Rahimi Hospital from March 2019 to March 2020. In this study, the data collection instrument was a researcher-designed form that included information such as age, history of recurrence, type of cancer, family history of cancer, personal history of cancer, lymph node involvement, hookah use history, smoking history, breastfeeding history, and material status. Finally, after collecting information, data was analyzed using SPSS software version 25. RESULTS: The average age of the patients in this study was 49.45 ± 6.01 years, and the youngest and oldest patients were 35 and 62 years, respectively. Among the studied patients, 34 individuals (57.63%) had Luminal A cancer, and 25 patients (42.37%) had triple negative cancer. Recurrence was reported in 23 patients (38.98%), and lymph node involvement was reported in 21 patients (35.59%). Moreover, 14 patients (23.73%) were positive for a personal history of cancer, and 22 patients (37.29%) had a family history of cancer. In this study, the relationship between recurrence and type of cancer and involvement of lymph nodes was statistically significant (P < 0.05). CONCLUSION: The rate of recurrence in patients with Luminal A cancer was higher than in patients with triple-negative cancer, according to the results of the study. More attention and periodic examinations in terms of recurrence in patients with Luminal A cancer were necessary.